14 March 2017
InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).
8 March 2017
InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Johan Giléus as new Chief Financial Officer (CFO) from May 1, 2017.
28 February 2017Genticel becomes “Genkyotex”: Genticel’s General Meeting approves the strategic combination with GenKyoTex SA
Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies (the “Company”), and GenKyoTex SA, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, announce that, at today’s Ordinary and Extraordinary General Meeting, Genticel’s shareholders approved the resolutions implementing the strategic combination between the two companies pursuant to the contribution agreement signed on December 22, 2016, as well as the change in the Company’s name from “Genticel” to “Genkyotex”.
28 February 2017
TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKI) as novel, locally-acting medicines for the treatment of chronic inflammatory gastrointestinal and ocular diseases, today announces the successful dosing of the first subjects in a Phase 1 study of its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).
27 February 2017Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV)
With Monoclonal Antibodies
Arsanis, Inc., a clinicalstage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and postinfection treatment of serious infectious diseases, and Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced today they have entered into an agreement under which Arsanis has secured the exclusive, worldwide license to antibodies targeting respiratory syncytial virus (RSV) that were discovered by Adimab. Arsanis will initially focus on the selection of a lead RSV antibody candidate and has received a grant of up to $9.3 million from the Bill & Melinda Gates Foundation to advance the selected antibody to IND filing.